Navigation Links
Spectral announces 2008 financial results
Date:3/12/2009

---------------------- Spectral Diagnostics Inc. Statements of Operations, Comprehensive Loss and Deficit For the years ended December 31, 2008 and 2007 ------------------------------------------------------------------------- (in thousands of dollars, except share and per share data) 2008 2007 $ $ Sales 3,011 2,993 Cost of sales 796 855 ---------------------------- Gross margin 2,215 2,138 ---------------------------- Operating expenses Selling, general and administrative 3,264 3,167 Amortization 592 536 Foreign exchange (gain) loss (117) 102 Stock-based compensation 110 117 Research and product development, net of tax credits 32 (59) ---------------------------- 3,881 3,863 ---------------------------- Loss before the following (1,666) (1,725) Interest expense on convertible notes payable (164) (165) Other net interest income 328 224 ---------------------------- Loss and comprehensive loss for the year (1,502) (1,666) Deficit - Beginn
'/>"/>
SOURCE Spectral Diagnostics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Spectral signs exclusive license agreement to bring sepsis therapeutic to the U.S. market
2. Surface plasmon resonances of metal nanoparticles in array can have narrower spectral widths
3. Spectral announces third quarter 2008 results
4. Spectral to bring anti-sepsis therapy to the U.S. market
5. Spectral announces exclusive distribution agreement in Russia for its EAA(TM) Sepsis Diagnostic Assay
6. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
7. Spectral announces presentation of data on improving sepsis patient management with EAA(TM) and Toraymyxin(TM) combination
8. Spectral and Toray expand collaboration to include new geographic territories
9. Spectrals EAA(TM) to be used in Phase III study for a sepsis anti-endotoxin therapy
10. Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on Intensive Care and Emergency Medicine
11. Spectral announces 2007 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... HAYWARD, Calif. and SHANGHAI ... Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, ... Phase 2 clinical study for its lead drug ... designed to treat drug-resistant bacteria such as MRSA ... safer and better tolerated therapeutic option than currently ...
(Date:8/31/2015)... 31, 2015 Trimb Healthcare AB ("Trimb") today ... YouMedical Group BV ("YouMedical"), a Dutch OTC company with ... sales of approximately EUR 16 million, with solid growth ... "Our ambition is to build a leading international OTC ... that goal. YouMedical gives us a stronger North European ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment option for ... first commercially available new FDA approved system in the last 14 years, and the ... high Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction rate of 98%, ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... announced the addition of the "Global & USA ... offering. The highly awaited US Biosimilar market ... highly awaited filigrastim biologic, Zarxio. How will the global ... The author reveals that biosimilars could save the US ...
Breaking Biology Technology:MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Global & USA BioSimilar Market Analysis Report 2015-2021 2Global & USA BioSimilar Market Analysis Report 2015-2021 3
... , , ... Corporation (Pink Sheets: CGCP), a market leader in laser transmyocardial ... (Investigational Device Exemption) to the Food and Drug Administration to ... with refractory angina. The PHOENIX Combination Delivery System combines ...
... TAINAN, Taiwan, July 30 /PRNewswire-Asia/ -- Eli Lilly ... today that they have,reached an amicable resolution of ... ScinoPharm,s manufacture and sale of gemcitabine,hydrochloride around the ... of the settlement, Lilly has granted ScinoPharm a ...
... LAUSANNE, Switzerland and MEDFORD, Massachussets, July 30 ... companies with a focus on the development of ... Protein Technologies (MSM), a human,antibody drug discovery company ... announce the signature of an exclusive,agreement for the ...
Cached Biology Technology:Cardiogenesis Corporation Makes Pre-IDE Submission for PHOENIX Combination Delivery System 2Eli Lilly & Company and ScinoPharm Taiwan Ltd. Announce Settlement of Gemcitabine Litigation 2Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic 2Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic 3Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic 4
(Date:8/6/2015)... 2015  Today, U.S. Congressman Mike Honda ... to learn firsthand how Silicon Valley technologies can ... a world leader in multi-factor identity management and ... federal agencies and commercial organizations achieve new levels ... "The vast majority of network breaches can be ...
(Date:8/5/2015)... August 5, 2015 Transparency Market ... Recognition Market - Global Industry Analysis, Size, Share, Growth, ... for facial recognition is forecast to reach US$ 2,671.8 ... demand for surveillance systems by civil and government agencies. ... crimes and terrorist activities across the globe that would ...
(Date:8/3/2015)... 2015 Synaptics, Inc. (Nasdaq: SYNA ), ... that members of the executive management team will present ... Technology Leadership Forum on Tuesday, August 11, 2015 at ... at the Sonnenalp Resort in Vail, CO. ... forward-looking information. An audio webcast of the event will ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6
... at the Smithsonian,s National Zoo detected a secondary rise ... panda Mei Xiang (may-SHONG) earlier this month. The results ... to believe the hormone rise indicates that it would ... birth to a cub or comes to the end ...
... 20, 2008) The future of high-intensity x-ray science ... Department of Energy,s Argonne National Laboratory have devised a ... free electron laser oscillator (X-FELO) we are proposing can ... than currently operating machines," Argonne Distinguished fellow Kwang-Je Kim ...
... as temperatures warm along the East Coast of the ... less likely they are to keep pace with the ... the Manomet Center for Conservation Sciences analyzed changes in ... birds along the coast of eastern Massachusetts since 1970. ...
Cached Biology News:A novel X-ray source could be brightest in the world 2Birds migrate earlier, but some may be left behind as the climate warms rapidly 2